Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zafirlukast - AstraZeneca

Drug Profile

Zafirlukast - AstraZeneca

Alternative Names: Accolate; Accolate SR; Accoleit; Aeronix; Azimax; ICI 204219; Olmoran; Respix®; Vanticon; Zafirst

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antiallergics; Antiasthmatics; Tosyl compounds
  • Mechanism of Action Leukotriene D4 receptor antagonists; Leukotriene E4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 21 Nov 2010 Generic equivalent available in USA for Asthma
  • 18 Nov 2010 Generic equivalent approved in USA for Asthma
  • 27 Feb 2001 3 case reports of severe hepatitis have been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top